Thirteen tumors showed significant up-regulation in PDGFRB expression, as calculated using R software to compare the expression levels between normal and tumor samples, (Glioblastoma multiforme (GBM), Glioma (GBMLGG), Brain lower grade glioma (LGG), Stomach and esophageal carcinoma (STES), Stomach adenocarcinoma (STAD), Head and neck squamous cell carcinoma (HNSC), Kidney renal clear cell carcinoma (KIRC), Liver hepatocellular carcinoma (LIHC), Rectum adenocarcinoma (READ), Pancreatic adenocarcinoma (PAAD), Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (LAML), and CHOL)). This evidence concerns the gene PDGFRB and neoplasm.